Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia

Zhou, 2014, Identification and targeting leukemia stem cells: the path to the cure for acute myeloid leukemia, World J. Stem Cell., 6, 473, 10.4252/wjsc.v6.i4.473 Brachet-Botineau, 2019, A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells, Cancers, 11, 2043, 10.3390/cancers11122043 Thol, 2020, Treatment of relapsed acute myeloid leukemia, Curr. Treat. Options Oncol., 21, 66, 10.1007/s11864-020-00765-5 Kayser, 2022, Updates on targeted therapies for acute myeloid leukaemia, Br. J. Haematol., 196, 316, 10.1111/bjh.17746 Hosono, 2021, Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia, Int. J. Clin. Oncol., 26, 2131, 10.1007/s10147-021-02006-7 Philip, 2018, Cyclin-dependent kinase 8: a new hope in targeted cancer therapy?, J. Med. Chem., 61, 5073, 10.1021/acs.jmedchem.7b00901 Wu, 2021, Angel or Devil ? - CDK8 as the new drug target, Eur. J. Med. Chem., 213, 10.1016/j.ejmech.2020.113043 Kapoor, 2010, The histone variant macroH2A suppresses melanoma progression through regulation of CDK8, Nature, 468, 1105, 10.1038/nature09590 Nakamura, 2018, CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells, Oncotarget, 9, 13474, 10.18632/oncotarget.24414 Brägelmann, 2017, Pan-cancer analysis of the mediator complex transcriptome identifies CDK19 and CDK8 as therapeutic targets in advanced prostate cancer, Clin. Cancer Res., 23, 1829, 10.1158/1078-0432.CCR-16-0094 Zhang, 2022, Discovery of the novel 1H-Pyrrolo[2,3-b]pyridine derivative as a potent type II CDK8 inhibitor against colorectal cancer, J. Med. Chem., 65, 12095, 10.1021/acs.jmedchem.2c00820 Firestein, 2008, CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity, Nature, 455, 547, 10.1038/nature07179 Roninson, 2019, Identifying cancers impacted by CDK8/19, Cells, 8, 821, 10.3390/cells8080821 Inhibition of Cdk8 Mediator Kinase S Source Oncotarget So 2017 Jan 29.Pdf>.. Yu, 2021, Potent and orally bioavailable CDK8 inhibitors: design, synthesis, structure-activity relationship analysis and biological evaluation, Eur. J. Med. Chem., 214, 10.1016/j.ejmech.2021.113248 Yu, 2021, Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation, Eur. J. Med. Chem., 218, 10.1016/j.ejmech.2021.113391 Solum, 2020, New CDK8 inhibitors as potential anti-leukemic agents - design, synthesis and biological evaluation, Bioorg. Med. Chem., 28, 10.1016/j.bmc.2020.115461 Rzymski, 2017, SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains, Oncotarget, 8, 33779, 10.18632/oncotarget.16810 Cee, 2009, Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11, Angew Chem. Int. Ed. Engl., 48, 8952, 10.1002/anie.200904778 Dale, 2015, A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease, Nat. Chem. Biol., 11, 973, 10.1038/nchembio.1952 Mallinger, 2016, Discovery of potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19, J. Med. Chem., 59, 1078, 10.1021/acs.jmedchem.5b01685 Czodrowski, 2016, Structure-based optimization of potent, selective, and orally bioavailable CDK8 inhibitors discovered by high-throughput screening, J. Med. Chem., 59, 9337, 10.1021/acs.jmedchem.6b00597 Xie, 2022, Lessons learned from past cyclin-dependent kinase drug discovery efforts, J. Med. Chem., 65, 6356, 10.1021/acs.jmedchem.1c02190 Wingelhofer, 2018, Pharmacologic inhibition of STAT5 in acute myeloid leukemia, Leukemia, 32, 1135, 10.1038/s41375-017-0005-9 Yoshimoto, 2009, FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation, Blood, 114, 5034, 10.1182/blood-2008-12-196055 Park, 1987, Characteristics of cell lines established from human colorectal carcinoma, Cancer Res., 47, 6710 Bancerek, 2013, CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response, Immunity, 38, 250, 10.1016/j.immuni.2012.10.017